Sign In

Robert A Baiocchi MD, PhD


​ 

Robert A Baiocchi MD, PhD
Asst ProfessorCollege of Medicinerobert.baiocchi@osumc.edu
B404 Starling Loving Hall 320 W 10th Avenue Columbus OH 43210
Phone:614-292-1551Fax: 614-292-3312
  • Viral Oncology

General Research Interest

HIV/AIDS and immune deficiency associated malignancies, Experimental therapeutics of lymphoma, Viral oncogenesis

Research Description

Our laboratory program focuses on 3 major areas of research: (1) experimental therapeutics of lymphomas (epigenetics, antibodies, vaccine/immunotherapy); (2) mechanisms of Epstein-Barr virus driven B cell transformation; and (3) clinical research involving new methods to treat immune deficient patients (HIV/AIDS, post transplantation) who develop cancer.

Transinstitutional Work

Our trans-institutional collaborative work involves our participation in the National Cancer Institutes' AIDS Malignancy Consortium (AMC) and the Blood and Bone Marrow Transplantation Clinical Trials Network (BMT CTN).  As the institutional principal investigator of the AMC at Ohio State, i help develop new treatment protocols and manage patients with HIV/AIDS associated cancers.  I am part of a working group at the BMT-CTN developing clinical trials to perform autologous and allogeneic stem cell transplantation in HIV+ patients with refractory or relapsed lymphomas.

Current Publications

  • Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R, Christian BA, Penza S, Benson DM Jr, Flynn J, Andritsos LA, Devine SM, Blum KAAssociation of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.Bone Marrow Transplant in press 4/15/2013
  • Alinari L, Pant S, McNamara K, Kalmar JR, Marsh W, Allen CM, Baiocchi RALymphomatoid granulomatosis presenting with gingival involvement in an immune competent elderly male.Head Neck Pathol 6(4) 496-501 12/1/2012
  • Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn D, Baiocchi R, Grever MR, Lucas DMDual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.Clin Cancer Res 18(17) 4600-11 9/1/2012
  • Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai JP, Wolfson A, Lustberg ME, Wei L, Wilkins D, Campbell A, Arbogast D, Doyle A, Byrd JC, Grever MR, Shah MHA dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.Invest New Drugs 30(2) 629-38 4/1/2012
  • Alinari L, Baiocchi RA, Prætorius-Ibba MFTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?Autophagy 8(3) 416-7 3/1/2012
  • Alinari L, Christian B, Baiocchi RANovel targeted therapies for mantle cell lymphoma.Oncotarget 3(2) 203-11 2/1/2012
  • Tiwari R, Toppino A, Agarwal HK, Huo T, Byun Y, Gallucci J, Hasabelnaby S, Khalil A, Goudah A, Baiocchi RA, Darby MV, Barth RF, Tjarks WSynthesis, biological evaluation, and radioiodination of halogenated closo-carboranylthymidine analogues.Inorg Chem 51(1) 629-39 1/2/2012
  • Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, Mani R, Mao Y, Yu B, Quinion C, Towns WH, Chen CS, Goldenberg DM, Blum KA, Byrd JC, Muthusamy N, Praetorius-Ibba M, Baiocchi RAFTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.Blood 118(26) 6893-903 12/22/2011
  • Karkhanis V, Hu YJ, Baiocchi RA, Imbalzano AN, Sif SVersatility of PRMT5-induced methylation in growth control and development.Trends Biochem Sci 36(12) 633-41 12/1/2011